{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-171091","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2025-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.840327+00:00","generated_at":"2026-05-17T21:53:00.629940+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Allogene drops ALLO-647 after Grade 5 death; pivots to Dagger platform","bullets":["Grade 5 hepatic failure from adenovirus attributed to ALLO-647; FC+ALLO-647 arm closed in ALPHA3 study.","ALLO-647 removed from all ongoing and pipeline programs; no trial includes it.","ALPHA3 proceeds as randomized trial of cema-cel with standard FC vs observation.","Futility analysis on MRD conversion expected in first half 2026.","Over 50 clinical sites activated; next-gen AlloCAR T uses Dagger Platform to reduce lymphodepletion."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-171091","json":"https://secwatch.observer/filing/0001193125-25-171091.json","markdown":"https://secwatch.observer/filing/0001193125-25-171091.md","text":"https://secwatch.observer/filing/0001193125-25-171091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000119312525171091/0001193125-25-171091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000119312525171091/d75167d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:53:00.629940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}